Abstract
Hepatocellular carcinoma (HCC) is a highly aggressive malignancy with a poor prognosis and high mortality. At present, vaccination with tumor cell lysate (TCL) loaded dendritic cells (DC) has been shown to be an effective therapy against HCC. However, the ability of promoting the specific T cell immune response is rather weak, influencing the antitumor response. Thus, it is necessary to find a strategy to improve the antitumor effect of TCL-loaded DC. Activation of signal transducer and activator of transcription 3 (STAT3) significantly inhibits antitumor immune response and DC maturity. Nifuroxazide, an antidiarrheal agent, has been proved to directly inhibit STAT3 activation. Thus, we investigated whether nifuroxazide could improve the antitumor immune response in mice vaccinated with TCL-loaded DC. Our results showed that the administration of nifuroxazide and DC-loaded TCL could significantly improve the survival rate, inhibit the tumor growth, and prompt the antitumor immune responses in mice with orthotopically implanted hepatocarcinomas, possibly providing a new combination strategy to treat HCC.
Introduction
Hepatocellular carcinoma (HCC) remains a major clinical challenge due to its aggressive nature and the immunosuppressive environment of the liver. While dendritic cell (DC) vaccines loaded with tumor cell lysates (TCL) represent a promising immunotherapeutic approach, their clinical efficacy is often limited. A key molecular driver of this failure is the STAT3 (signal transducer and activator of transcription 3) pathway. Persistent STAT3 activation in the tumor microenvironment prevents DC maturation and suppresses the cytotoxic T-cell responses necessary for tumor clearance. This study explores the potential of nifuroxazide, a known STAT3 inhibitor, to act as an adjuvant that enhances the efficacy of TCL-loaded DC vaccines.
Methods
The researchers utilized a combination of in vitro and in vivo techniques to evaluate the synergistic effects of nifuroxazide and DC vaccination.
- In Vitro Characterization: Human HepG2 and mouse H22 hepatoma cells were treated with varying concentrations of nifuroxazide. Cell viability was assessed using CCK8 assays, and migratory capacity was measured via wound healing assays.
- DC Vaccine Preparation: Bone marrow-derived DCs from C57BL/6 mice were pulsed with H22 tumor cell lysates (TCL).
- Orthotopic Mouse Model: To simulate the human disease environment accurately, H22 tumor fragments were implanted directly into the livers of C57BL/6 mice.
- Therapeutic Regimen: Mice were treated with PBS (control), nifuroxazide alone, TCL-loaded DCs alone, or a combination of both.
- Immune Profiling: Flow cytometry and ELISA were used to quantify immune cell populations (CD4+, CD8+, NK cells) and cytokine levels (IFN-γ, TNF-α, VEGF), respectively.
Key Results
The study demonstrated that nifuroxazide exerts both direct antitumor effects and potent immunomodulatory activity.
- Direct Antitumor Activity: In vitro assays confirmed that nifuroxazide significantly reduced cell viability and inhibited the migration of H22 cells in a dose-dependent manner. The wound healing assay demonstrated that nifuroxazide-treated cells were significantly less capable of closing the experimental gap over 48 hours compared to controls. Nifuroxazide suppresses the migration of H22 cells as shown by the wound healing assay. Source, p. 4
- Enhanced Survival and Tumor Inhibition: In the orthotopic mouse model, the combination of nifuroxazide and the DC vaccine resulted in a 58.3% survival rate at 40 days, significantly higher than the control (25%) or monotherapy groups. This group also exhibited the lowest tumor weights.
- Systemic Immune Activation: The combination therapy significantly increased the infiltration of CD4+ and CD8+ T cells into tumor tissues. Furthermore, it boosted systemic levels of pro-inflammatory cytokines (IFN-γ, TNF-α) while reducing the pro-angiogenic factor VEGF.
Key Insights and Discussion
The findings highlight STAT3 as a critical gatekeeper in HCC immunotherapy. By repurposing nifuroxazide as a STAT3 inhibitor, the researchers were able to "unmask" the tumor, allowing the DC vaccine to induce a robust systemic immune response. This combination therapy not only promotes apoptosis (evidenced by increased cleaved caspase-3) but also alters the tumor secretome to inhibit angiogenesis and metastasis (reduced VEGF and MMP2).
While these results are promising, further research is required to optimize human dosing and evaluate long-term immune memory. Nonetheless, this study provides a strong theoretical and experimental foundation for using nifuroxazide as a clinical adjuvant to improve the outcomes of DC-based vaccines in HCC patients.
Summary updated